Corporate Information

Growth Initiatives

DEVELOPMENT OF DIFFERENTIATED GENERICS AS CORE OFFERING TO:

Enhance product life cycle

Increase patient convenience

Improve adherence to treatment

ENHANCEMENT OF OUR MARKETING EFFORTS THROUGH:

Building marketing partnerships for the pre-formulation intermediates and finished formulations in the RoW & pharmerging markets.

Establishing our presence in the regulated markets through both pharmaceutical & nutraceutical products

Developing products that are valuable to business partners & patients across markets.

Enhancing R&D capabilities to eventually launch products in developed markets.
Investing more in product development to strengthen the product pipeline.
Expanding the portfolio of existing products’ pipeline by adding more novel and differentiated generic products.
Increasing investment in innovative process technology platform for continued enabling of differentiated products opportunities

Expanding finished formulation business across several countries in MENA, SEA, CIS, Francophone and LATAM regions.
Entering into marketing tie-ups through joint venture arrangements, partnerships, authorizations for specific markets,
out-licensing of ready dossiers to capture more of the value chain.
Launch of ZIM’s brands through own or co-marketing initiatives.

EXPAND CAPACITY WITH OPERATING FLEXIBILITY

Capacity expansion by adding latest manufacturing equipment required for supply to Pharmerging and Developed markets within our EU GMP registered facility.

Bring flexibility in manufacturing of PFI and FF in small batches for export to various markets under a dedicated small-batch manufacturing (SBM) set up.

ELLEVATE OUR QUALITY ASSURANCE (QA) AND QUALITY CONTROL (QC) SYSTEMS

Internal reorganization & upgrading of certain facilities for improved audit and compliance.

Develop partnership with alternate API vendors that cater to Pharmerging and Developed markets for higher quality supplies.

Streamlining the integrated ERP solution to bring more transparency in operations & financial processes in line with the requirements of regulators and customers.

Continued investment in latest testing equipment, team of experienced manpower and training in the QA and QC departments.

Mr. Zulfiquar Kamal

Director - Finance

A chartered accountant, Zulfiquar Kamal has been associated with the company for over 25 years. He has been on the Board of Directors since 1991. With his financial acumen, refined over an experience of more than three decades, he brings to the table the financial discipline and control necessary for a growing organization like ZIM Labs. In his current role as Director – Finance, Mr. Kamal oversees the commercial operations of the company. He envisions ZIM Labs to be a financially efficient organization known for its operational efficiencies and technological process.

Mr. Niraj Dhadiwal

Director - Business Development

Mr. Niraj Dhadiwal is a pharmacy graduate with a diploma in business management and has been with the company for nearly three decades. He started his career with ZIM Labs as a production officer in 1991, rising through ranks to his current position of Director. With his keen business acumen and technical knowledge, Mr. Dhadiwal has played a key role in the export-development arm of the company. His contribution to the development of overseas business stands unmatched and a testament to his foresight and ability to tap into new markets. In his current role as Director – Business Development, Mr. Dhadiwal looks after the business development and marketing functions of the company. He envisions ZIM Labs to have a global presence with innovative and differentiated products leading to good returns for all the stakeholders.

Mr. Prakash Sapkal

Director - Operations

Mr. Prakash Sapkal is a Pharmacy graduate with post-graduation in Business Administration. He is associated with the Company for 26 years starting his career as Assistant Chemist. During all these years he has handled key operations in various capacities like Production Supervisor, Production Manager, and Vice President – Operations. His major contribution has been in assembling a team that has brought the vision of ZIM Labs to life.

Mrs. Kavita Loya

Independent Director

Kavita Loya is a Senior Practicing Chartered Accountant with 20 years of experience. She is on the Board as an Independent Director. She is presently a Partner in Loya Bagri & Company, Chartered Accountants. She is a Member of Capacity Building Committee of the Western Region of ICAI, Mumbai & Women’s Empowerment Committee, Nagpur Chapter.

Mr. Padmakar S. Joshi

Independent Director

Padmakar Joshi is a senior banking professional with more than 37 years of rich and multi-functional experience in areas of commercial banking. He is on the Board as an Independent Director. He retired as Dy. Head- Corporate & SME Credit Monitoring and Debt Restructuring, Union Bank of India.

Dr. Kamlesh Shende

Independent Director

Dr. Shende has a Doctorate in Herbal Medicines and has over 30 years of experience in the pharmaceutical sector. He is on the Board as an Independent Director. He is retired as Joint Commissioner (Drugs) Mumbai - Food Drugs Administration.

Dr. Kakasaheb Mahadik

Independent Director

With a Doctorate in Pharmaceutical Chemistry and Law and over 30 years of experience in academics, Dr. Mahadik is on the Board of Directors as an Independent Director. He is now retired from academics.

Management Committee

Mr. Pradeep Kataria

Senior Vice President – Operations

Mr.Pradeep Kataria is a postgraduate in pharmacy with an association of more than 26 years with the organization. Mr.Kataria joined ZIM as Production Supervisor in 1995.

He has been a hands-on leader of the Operations team and has been involved in successful scale-ups of pellets and taste-masking technologies developed by the company . He has also been a meticulous administrator in developing, maintaining and managing in accordance with the high standards required for various accreditations.In his current role, Mr Kataria, with his problem-solving and administration skills, looks after day-to-day activities of the plant, including manufacturing, external audits and internal coordination amongst operational departments.

Mr. Shyam Mohan Patro

Chief Financial Officer – Accounts and Finance

Mr.Patro is the CFO of ZIM and has been with the Company since April 2019.He is a Qualified Cost Accountant and Company Secretary.

He has also completed M.Sc. in Applied Mathematics form NIT Rourkela and EPBM from IIM Kolkata. He has over 23 years of experience in diversified areas covering finance, taxation, legal, commercial and control functions and is responsible for these functions in Zim Laboratories.

Mr. Vijay Fudke

Senior Vice President – Technical Services

Mr.Vijay Fudke is a pharmacy graduate with an association of more than 25 years with ZIM. Having spent his initial years in the field of quality control, Mr.Fudke joined ZIM as a Quality Assurance (QA) Officer in 1996.

He has played an instrumental role in the achievement of various accreditations by the company, such as the EU-GMP, WHO-GMP & ISO 9001:2008. In his current role as Senior Vice President – Technical Services, Mr.Fudke is involved in providing clients with technical services like molecule selection for development, business expansion and high-level technical query resolution.

Income Statements

Standalone Quarterly Income Statements

Particular	FY 2020				FY 2021				FY 2022
Particular	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
Income from Operations	652	621	681	624	654	818	701	710	624	751	852	1,016
Other Operating Income	17	52	41	55	44	46	41	22	12	7	8	25
Total Income from Operations	669	673	722	679	698	864	742	732	636	758	860	1,041
Operating Cost	631	625	647	596	594	751	660	638	574	662	746	888
EBIDTA	38	48	75	83	104	113	82	94	62	96	114	153
EBIT	7	17	40	47	68	78	45	55	28	55	79	114
Finance costs	32	32	32	30	29	27	23	30	25	26	18	14
Profit/(Loss) before exceptional item & tax	(25)	(15)	8	17	39	51	22	25	3	29	61	100
Exceptional Item	-	-	-	-	-	52	-	-	-	-	-	-
Profit/(Loss) before tax	(25)	(15)	8	17	39	(1)	22	25	3	29	61	100

INR in Millions

Standalone Half Yearly Income Statements

Particular	FY 2018		FY 2019		FY 2020		FY 2021		FY 2022
Particular	H1	H2	H1	H2	H1	H2	H1	H2	H1	H2
Income from Operations	1,234	1,416	1,373	1,854	1,273	1,305	1,472	1,411	1375	1868
Other Operating Income	29	41	37	53	69	96	90	63	19	33
Total Income from Operations	1,263	1,457	1,410	1,907	1,342	1,401	1,562	1,474	1,394	1,901
Operating Cost	1,099	1,247	1,227	1,645	1,256	1,243	1,345	1,298	1,236	1,634
EBIDTA	164	210	183	262	86	158	217	176	158	267
EBIT	117	159	128	205	24	87	146	100	83	193
Finance costs	49	45	55	50	64	62	56	53	51	32
Profit/(Loss) before exceptional item & tax	68	114	73	155	(40)	25	90	47	32	161
Exceptional Item	-	(59)	-	-	-	-	52	-	-	-
Profit/(Loss) before tax	68	173	73	155	(40)	25	38	47	32	161

INR in Millions

Standalone Yearly Income Statements

Particular	FY 2018	FY 2019	FY 2020	FY 2021	FY 2022
Income from Operations	2,650	3,227	2,578	2,883	3,243
Other Operating Income	70	90	165	153	52
Total Income from Operations	2,720	3,317	2,743	3,036	3,295
Operating Cost	2,346	2,872	2,499	2,643	2,870
EBIDTA	374	445	244	393	425
EBIT	276	333	111	246	276
Finance costs	94	105	126	109	83
Profit/(Loss) before exceptional item & tax	182	228	(15)	137	193
Exceptional Item	(59)	-	-	52	-
Profit/(Loss) before tax	241	228.00	(15)	85	193

INR in Millions

Standalone Half Yearly Statements of Financial Positions

Total assets	2,968	2,974	3,202	3,248	3,376	3,229	3,223	3,203	3,167	3,354
Particular	FY 2018		FY 2019		FY 2020		FY 2021		FY 2022
Particular	H1	H2	H1	H2	H1	H2	H1	H2	H1	H2
Property, plant and equipment including Capital work-in-progress	936	977	1,079	1,072	1,114	1,122	1,079	1,052	1,063	1,068
Intangible assets including Intangible assets under development	27	47	61	69	79	87	83	84	76	79
Other Non-Current Assets	135	229	121	195	256	257	255	237	207	201
Current Assets	1,870	1,721	1,941	1,912	1,927	1,763	1,806	1,830	1,821	2,006
Equity	1,223	1,360	1,407	1,512	1,500	1,518	1,544	1,570	1,590	1,701
Borrowings	895	811	890	772	907	899	802	811	864	512
Other Non- Current Liabilities	-	-	-	-	4	6	5	2	-	11
Current Liabilities	850	803	905	964	965	806	872	820	713	1,130
Total equity and liabilities	2,968	2,974	3,202	3,248	3,376	3,229	3,223	3,203	3,167	3,354

INR in Millions

Standalone Yearly Statements of Financial Positions

Total assets	2,974	3,248	3,229	3,203	3,354
Particular	FY 2018	FY 2019	FY 2020	FY 2021	FY 2022
Property, plant and equipment including Capital work-in-progress	977	1,072	1,122	1,052	1,068
Intangible assets including Intangible assets under development	47	69	87	84	79
Other Non-Current Assets	229	195	257	237	201
Current Assets	1,721	1,912	1,763	1,830	2,006
Equity	1,360	1,512	1,518	1,570	1,701
Borrowings	811	772	899	811	512
Other Non- Current Liabilities	-	-	6	2	11
Current Liabilities	803	964	806	820	1,130
Total equity and liabilities	2,974	3,248	3,229	3,203	3,354

INR in Millions

CORPORATE INFORMATION

Growth Initiatives,
Team and Progress

Growth Initiatives

BOARD OF DIRECTORS